IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells.
about
Following a TRAIL: update on a ligand and its five receptorsAbsence of gene mutation in TRAIL receptor 1 (TRAIL-R1) and TRAIL receptor 2 (TRAIL-R2) in chronic myelogenous leukemia and myelodysplastic syndrome, and analysis of mRNA Expressions of TRAIL and TRAIL-related genes in chronic myelogenous leukemia.Molecular targets for selective killing of TRAIL-resistant leukemic cells.Maternal plasma soluble TRAIL is decreased in preeclampsia.Soluble TRAIL in normal pregnancy and acute pyelonephritis: a potential explanation for the susceptibility of pregnant women to microbial products and infection.Three-dimensional microscopy characterization of death receptor 5 expression by over-activated human primary CD4+ T cells and apoptosis.RA-inducible gene-I induction augments STAT1 activation to inhibit leukemia cell proliferationThe role of cell type-specific responses in IFN-β therapy of multiple sclerosis.Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophilsSoluble TRAIL Concentration in Serum Is Elevated in People with Hypercholesterolemia.Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL.Experimental Neuromyelitis Optica Induces a Type I Interferon Signature in the Spinal Cord.Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis.Bladder Cancer Immunotherapy: BCG and Beyond.TNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice.IFNα enhances the production of IL-6 by human neutrophils activated via TLR8.Role of neutrophils in BCG immunotherapy for bladder cancer.Intraindividual dynamics of transcriptome and genome-wide stability of DNA methylation.TRAIL, DR4 and DR5 are upregulated in kidneys from patients with lupus nephritis and exert proliferative and proinflammatory effects.Therapeutic applications of TRAIL receptor agonists in cancer and beyond.Death receptor pathways mediate targeted and non-targeted effects of ionizing radiations in breast cancer cells.Type I interferons and interferon regulatory factors regulate TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected macrophagesTRAIL gene therapy: from preclinical development to clinical application.TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.Premature vascular damage in systemic lupus erythematosus.Neutrophils recruited by IL-22 in peripheral tissues function as TRAIL-dependent antiviral effectors against MCMV.Regulation of the human TRAIL gene.Targeting neutrophil apoptosis for enhancing the resolution of inflammation.Neutrophil-derived cytokines: facts beyond expression.Significance of serum tumor necrosis factor-related apoptosis-inducing ligand as a prognostic biomarker for renal cell carcinoma.Osteoprotegerin: A novel biomarker for inflammatory bowel disease and gastrointestinal carcinoma.Molecular mechanism of ER stress-induced gene expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in macrophages.NKG2D regulates production of soluble TRAIL by ex vivo expanded human γδ T cells.Lactobacillus strains induce TRAIL production and facilitate natural killer activity against cancer cells.Mast cells dysregulate apoptotic and cell cycle genes in mucosal squamous cell carcinoma.Apo2L/TRAIL is an indirect mediator of apoptosis induced by interferon-alpha in human myeloma cells."Combination-oriented molecular-targeting prevention" of cancer: a model involving the combination of TRAIL and a DR5 inducer.Combination of isoliquiritigenin and tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis in colon cancer HT29 cells.Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2LSystems approach to uncover signaling networks in primary immunodeficiency diseases.
P2860
Q28292767-19624AF1-DC95-42E9-A508-AE81CF92076EQ33213461-89195A52-66FB-43FC-A793-C98C96845D85Q33891400-66B9B391-C351-42C0-A555-915EB53A9709Q33909572-A2669416-DBAF-4C8B-A333-E4AAE50D8798Q33910907-85820B2D-A08F-470E-BFC8-D6D8ECD22C94Q34193462-8C80FFDE-C813-448C-9073-1D6B78D8BD9DQ34550058-C8EE28FD-CFAD-4B10-8981-D8303E5AD307Q35621233-61FD73B3-6D7C-4492-A760-E80D4496906AQ35689498-475D22F4-E3F9-40F0-BFC7-943F2A6CCF23Q35859880-9F7CF30F-1E2B-43FF-A224-FDA9DB769120Q35909089-7920BF52-286A-43A6-9F04-CA169B39BC20Q35962565-050CCE0D-8961-4405-9E8D-FDF17310DC8BQ36059617-163A93A4-5DD2-4379-A663-7A523395B9EEQ36072179-F0BB7936-4CEF-4518-A00D-54596C984122Q36340830-27067D71-5810-42D6-8D91-A3FF6971995FQ36501033-ACD419B3-D29B-4192-9A1E-A3BB23B162DCQ36803793-686B84CE-F6F7-4A85-BF21-DB4FED57C10CQ36914953-B0ECE76E-2BDD-45E7-B938-1D948D8A2A12Q37072767-7EAE1A4C-E72C-438F-B9A1-753B8A3DA50AQ37114025-5C37FB90-C55D-4958-BC01-E72C56FBE451Q37116325-924E7EFE-EB1D-497F-AA19-DF5B06C61F77Q37168039-8DF2509F-C89D-4197-BC86-5FA0BC28F01DQ37307340-8B7B7FAF-5F92-49ED-951D-5378E06C24DBQ37440765-C5DE2EB5-172F-44AA-8281-2943054005D4Q37573524-6F95E881-D875-4AAE-8B2E-65162F96AF42Q37706595-55A4066B-6123-4CC5-9FEF-AFE5B6B07565Q38034651-AFDA9505-5DA3-460B-88B0-63D31BEBA20CQ38202818-82CE5B47-D168-4E43-90AF-BA73EBA10CE7Q38265504-9C78CAE2-486B-43F2-B707-E186FEC45406Q38292479-2A5BFE1D-135A-437D-AC94-04FA4126905AQ38741874-B04B4FDD-D025-4A2E-9005-2EEA60A97468Q38892534-F423E112-2A51-490E-9B95-7AFEA20C0360Q39098092-AC195871-E404-4704-8CF0-82E7BC326818Q39765675-3EA545C0-8C0A-4D98-9286-5EB828B295D4Q40193455-68F564C3-6C7C-4E77-A482-7DA54B5E5CF1Q40358490-64BB43A6-03DF-4BDF-A56A-047555C9DD45Q41119138-CA8C6758-ADEE-4FF5-91E6-82E0B285AEE1Q41377344-36511DC9-6905-4656-A2E9-40154AA1709BQ42194180-1ABEED93-B5B2-4C87-B054-33CC702C99A1Q43409889-38A33F79-C144-42CA-BF45-FDEF6CC7A497
P2860
IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
IFNalpha-stimulated neutrophil ...... ic activity on leukemic cells.
@ast
IFNalpha-stimulated neutrophil ...... ic activity on leukemic cells.
@en
IFNalpha-stimulated neutrophil ...... ated apoptosis-inducing ligand
@nl
type
label
IFNalpha-stimulated neutrophil ...... ic activity on leukemic cells.
@ast
IFNalpha-stimulated neutrophil ...... ic activity on leukemic cells.
@en
IFNalpha-stimulated neutrophil ...... ated apoptosis-inducing ligand
@nl
prefLabel
IFNalpha-stimulated neutrophil ...... ic activity on leukemic cells.
@ast
IFNalpha-stimulated neutrophil ...... ic activity on leukemic cells.
@en
IFNalpha-stimulated neutrophil ...... ated apoptosis-inducing ligand
@nl
P2093
P50
P921
P1433
P1476
IFNalpha-stimulated neutrophil ...... ic activity on leukemic cells.
@en
P2093
Cristina Tecchio
Daniela Margotto
Federica Calzetti
Giovanni Pizzolo
Giuseppe Todeschini
Lorenzo Pilla
Marco A Cassatella
Patrizia Scapini
P304
P356
10.1182/BLOOD-2003-08-2806
P407
P577
2004-01-15T00:00:00Z